LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) Financial Statements — Income, Balance Sheet, Cash Flow

Overview Financials Chart Business Summary Filings Ownership Valuation

Financial Statements — LFCR

Balance Sheet

(in millions USD)

Metric	Q2 2026	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q3 2022	Q2 2022	Q1 2022	Q3 2021	Q2 2021	Q1 2021
Cash & Equivalents	17.24	20.80	5.42	9.46	5.52	3.07	3.22	8.64	2.95	6.83	1.85	1.09	4.22	2.25	2.49	0.59
Accounts Receivable	--	--	--	30.30	25.15	--	--	--	32.37	35.69	49.56	65.28	40.93	69.58	66.55	65.03
Inventory	25.48	28.16	34.60	39.21	41.64	39.67	41.45	41.69	48.70	77.52	73.70	79.43	64.29	76.78	71.20	60.00
Total Current Assets	83.69	77.64	84.21	81.86	74.18	76.16	76.71	82.81	88.44	127.09	132.04	154.52	116.60	162.93	154.19	147.37
Property, Plant & Equipment	123.71	125.51	128.22	150.58	148.76	145.37	142.91	136.26	120.80	118.85	123.21	179.93	117.55	168.69	170.97	171.41
Goodwill	13.88	13.88	13.88	13.88	13.88	13.88	13.88	13.88	13.88	13.88	33.92	37.33	13.88	69.39	69.39	69.39
Intangible Assets	--	4.20	4.20	4.20	4.20	4.20	4.20	4.20	--	--	--	--	--	11.29	11.78	12.28
Total Non-current Assets*	145.81	147.86	153.48	173.53	172.64	170.08	169.10	162.81	147.71	151.98	193.55	267.60	152.50	346.90	344.97	358.81
Total Assets	229.50	225.50	237.69	255.39	246.82	246.24	245.82	245.62	236.15	279.07	325.58	422.12	269.10	509.82	499.16	506.18
Accounts Payable	7.53	7.01	7.41	14.97	18.01	15.69	19.02	15.69	14.76	27.97	20.01	59.10	16.37	56.32	60.89	50.72
Total Current Liabilities	21.64	20.50	31.12	35.29	40.52	36.81	40.25	35.41	37.67	195.70	90.07	122.26	178.96	125.35	173.91	153.73
Long-term Debt	155.07	148.74	124.94	111.30	106.32	97.11	92.86	88.83	98.96	98.95	79.60	124.19	98.57	145.05	93.19	104.95
Total Non-current Liabilities*	191.77	184.22	159.15	160.34	166.80	150.00	163.22	183.65	125.76	9.21	91.45	143.66	9.77	179.85	116.31	131.29
Total Liabilities	213.41	204.72	190.27	195.63	207.32	186.81	203.47	219.07	163.44	204.91	181.51	265.92	188.73	305.20	290.22	285.02
Retained Earnings	(244.34)	(238.18)	(204.09)	(191.46)	(182.75)	(159.44)	(175.07)	(189.29)	(140.09)	(99.90)	(22.19)	(9.34)	(87.45)	41.45	46.94	60.25
Total Stockholder Equity	(34.09)	(28.44)	2.23	15.45	(3.94)	17.69	1.42	(13.56)	34.21	74.17	144.07	156.20	80.36	204.62	208.94	221.16

* Derived from reported values

Income Statement

(in millions USD) (except per-share rows)

Metric	Q2 2026	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021
Total Revenue	34.17	23.19	35.15	32.56	24.71	37.89	35.70	30.15	24.52	25.52	27.60	38.80	(38.41)	53.07	129.49	43.36	139.83	137.78	130.90	135.64
Cost of Revenue	22.09	18.73	25.31	21.48	19.32	20.61	23.81	20.19	21.79	17.11	21.62	31.69	(51.46)	39.18	116.50	37.10	115.03	118.09	110.27	119.30
Gross Profit	12.08	4.46	9.85	11.08	5.39	17.27	11.89	9.96	2.73	8.41	5.98	7.11	13.05	13.90	12.99	6.25	24.80	19.69	20.64	16.35
Research & Development	1.54	1.22	2.05	1.92	2.19	2.16	2.17	2.10	2.15	2.61	1.96	2.12	1.19	2.06	2.72	2.05	2.58	2.56	2.57	2.51
Selling, General & Admin	7.97	7.92	10.09	11.12	14.79	12.22	9.85	9.19	9.21	7.77	10.97	10.77	13.10	9.73	13.84	10.66	16.14	15.22	16.11	17.90
Total Operating Expenses	9.51	9.13	48.89	13.04	16.97	15.12	12.79	11.44	11.34	9.65	15.68	15.01	28.17	17.65	50.02	13.76	23.57	20.48	22.10	28.82
Operating Income	2.57	(4.67)	(9.03)	(1.96)	(11.58)	2.15	(0.89)	(1.48)	(8.61)	(1.23)	(9.70)	(7.91)	(15.12)	(3.75)	(37.03)	(7.50)	1.23	(0.79)	(1.47)	(12.47)
Interest Expense	--	--	--	--	--	--	--	--	--	3.93	5.82	4.22	2.24	4.11	4.33	3.68	--	4.18	3.04	3.11
Pretax Income	(6.13)	(14.94)	(14.78)	(6.53)	(16.25)	(7.14)	15.00	14.18	(12.52)	(29.29)	(15.39)	(12.44)	(11.54)	(7.38)	(41.26)	(11.35)	(3.44)	(5.71)	(16.00)	(15.31)
Tax Provision	0.02	0.04	(0.01)	0.04	(0.02)	(0.06)	0.22	(0.06)	0.09	0.23	0.07	0.00	(1.19)	(0.28)	(2.82)	0.00	(0.57)	(0.22)	(2.70)	(4.31)
Net Income	(6.16)	(14.98)	(14.77)	(6.57)	(16.23)	(7.08)	15.63	14.22	(10.75)	(35.57)	(40.19)	(12.45)	(53.91)	(12.85)	(38.44)	(11.35)	(2.87)	(5.50)	(13.30)	(11.00)
Basic EPS	(0.19)	(0.43)	(0.47)	(0.25)	(0.53)	(0.23)	0.51	0.47	(0.35)	(1.18)	(1.33)	(0.42)	(1.45)	(0.24)	(1.30)	(0.38)	(0.10)	(0.19)	(0.45)	(0.38)
Diluted EPS	(0.19)	(0.43)	(0.47)	(0.25)	(0.53)	(0.14)	0.42	0.39	(0.35)	(1.18)	(1.33)	(0.42)	(1.26)	(0.43)	(1.30)	(0.38)	(0.10)	(0.19)	(0.45)	(0.38)

Cash Flow Statement

(in millions USD)

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021
Operating Cash Flow	(2.19)	4.70	5.35	(5.55)	(6.11)	(0.64)	8.64	(1.53)	1.01	(8.33)	(0.27)	(12.69)	(4.48)	0.04	(20.13)	(5.14)	(1.53)	4.42	(7.86)	1.44
Capital Expenditures	0.51	1.12	2.10	11.32	2.47	3.39	--	6.25	3.98	5.05	--	6.14	6.18	7.69	5.53	5.10	2.93	12.39	3.98	2.78
Free Cash Flow*	(2.70)	3.58	3.25	(16.87)	(8.58)	(4.03)	--	(7.78)	(2.97)	(13.38)	--	(18.82)	(10.66)	(7.65)	(25.66)	(10.23)	(4.46)	(7.97)	(11.83)	(1.35)
Investing Cash Flow	(0.51)	(1.12)	(2.10)	(4.32)	(2.47)	(3.39)	(2.64)	(6.25)	(3.98)	(5.05)	(8.16)	6.39	(3.05)	(19.39)	67.99	(5.10)	0.21	(12.36)	(3.98)	5.25
Financing Cash Flow	(0.85)	(0.26)	(0.40)	6.83	12.52	1.09	(0.61)	7.64	(2.45)	2.93	24.57	2.41	12.72	19.14	(47.09)	9.88	3.91	6.99	11.59	(4.97)

* Derived from reported values